Synapse - Kenneth Yu

Results (165)

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

Journal Article

Mondaca, S.; Margolis, M.; Sanchez-Vega, F.; Jonsson, P.; Riches, J. C.; Ku, G. Y.; Hechtman, J. F.; Tuvy, Y.; Berger, M. F.; Shah, M. A.; more...
Gastric Cancer (2019)

Fulltext@MSK | Save

Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers

Journal Article

Lowery, M. A.; Bradley, M.; Chou, J. F.; Capanu, M.; Gerst, S.; Harding, J. J.; El Dika, I.; Berger, M.; Zehir, A.; Ptashkin, R.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

Weighing the risks and benefits of neoadjuvant therapy in resectable pancreatic cancer: Neoadjuvant therapy should not be used as part of standard clinical practice

Journal Article

Elarre, P. S.; Yu, K. H.
Oncology (Norwalk) (2018)

Fulltext@MSK | Save

HuMab-5B1 (MVT-5873), a mAb targeting sLe(a), in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies

Meeting Abstract

O'Reilly, E. M.; Borazanci, E. H.; Yu, K. H.; Varghese, A. M.; Estrella, H.; Kamins, D.; Melink, T.; Dorr, K.; Maffuid, P.; Gutheil, J.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis

Meeting Abstract

Yu, K. H.; Mantha, S.; Tjan, C.; Kaufmann, E. S.; Brenner, R.; Lowery, M. A.; Ku, G. Y.; Raj, N. P.; Shcherba, M.; Goldberg, Z.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Prospective analysis of somatic and germline genetic alterations in patients with ampullary carcinomas

Meeting Abstract

Wong, W.; O'Reilly, E. M.; Varghese, A. M.; Yu, K. H.; Iacobuzio-Donahue, C. A.; Shia, J.; Klimstra, D.; Allen, P. J.; Lowery, M. A.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC)

Meeting Abstract

Krantz, B. A.; Tsui, D.; Lowery, M. A.; Capanu, M.; Yu, K. H.; Kelsen, D. P.; Gedvilaite, E.; Zhang, L.; Selcuklu, S. D.; You, D.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Genome wide cis-regulatory elements accessibility signature predicts early recurrence of the treatment-naïve resected subset of PDAC: A new paradigm for precision oncology

Meeting Abstract

Dhara, S.; Chhangawala, S.; Askan, G.; Liguo, Z.; Sinha, S.; Glassman, D.; Yu, K.; Balachandran, V.; Leslie, C.; Leach, S.
Cancer Research (2018)

Fulltext@MSK | Save

A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis